Waldenstrom macroglobulinemia

Common Name(s)

Waldenstrom macroglobulinemia

Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder. It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy, fever, Raynaud's phenomenon, and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition. Treatment is often reserved for those with symptoms and may include various medications including corticosteroids, alkylating agents, biologic response modifiers and purine analogues.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Waldenstrom macroglobulinemia" for support, advocacy or research.

International Waldenstrom's Macroglobulinemia Foundation

To offer mutual support and encouragement to the Waldenstrom's macroglobulinemia community and others with an interest in the disease. To provide information and educational programs that address patients' concerns. To promote and support research leading to better treatments and ultimately a cure.

http://www.iwmf.com

Last Updated: 16 Jul 2014

View Details

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Waldenstrom macroglobulinemia" returned 137 free, full-text research articles on human participants. First 3 results:

Bing-Neel syndrome: a rare complication of Waldenström macroglobulinemia.
 

Author(s): Sergio Sánchez-Guerrero, Jorge J Castillo

Journal: Blood. 2015 Sep;126(11):1390.

 

Last Updated: 24 Nov 2015

Go To URL
Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study.
 

Author(s): Efstathios Kastritis, Maria Gavriatopoulou, Marie-Christine Kyrtsonis, Maria Roussou, Evdoxia Hadjiharissi, Argyris Symeonidis, Panagiotis Repoussis, Evridiki Michalis, Sosana Delimpasi, Konstantinos Tsatalas, Panagiotis Tsirigotis, Amalia Vassou, Elina Vervessou, Eirini Katodritou, Dimitra Gika, Evangelos Terpos, Meletios A Dimopoulos

Journal: Blood. 2015 Sep;126(11):1392-4.

 

Last Updated: 11 Sep 2015

Go To URL
Rare Circulating Cells in Familial Waldenström Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization.
 

Author(s): Maroulio Pertesi, Perrine Galia, Nicolas Nazaret, Maxime Vallée, Laurent Garderet, Xavier Leleu, Hervé Avet-Loiseau, Matthieu Foll, Graham Byrnes, Joel Lachuer, James D McKay, Charles Dumontet

Journal:

 

The MYD88 L265P is a recurrent somatic mutation in neoplastic cells from patients with Waldenström Macroglobulinemia (WM). We identified the MYD88 L265P mutation in three individuals from unrelated families, but its presence did not explain the disease segregation within these WM ...

Last Updated: 10 Sep 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Waldenstrom macroglobulinemia" returned 20 free, full-text review articles on human participants. First 3 results:

Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO).
 

Author(s): Laurence Simon, Aikaterini Fitsiori, Richard Lemal, Jehan Dupuis, Benjamin Carpentier, Laurys Boudin, Anne Corby, Thérèse Aurran-Schleinitz, Lauris Gastaud, Alexis Talbot, Stéphane Leprêtre, Béatrice Mahe, Camille Payet, Carole Soussain, Charlotte Bonnet, Laure Vincent, Séverine Lissandre, Raoul Herbrecht, Stéphane Kremer, Véronique Leblond, Luc-Matthieu Fornecker

Journal: Haematologica. 2015 Dec;100(12):1587-94.

 

Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome. There is currently no consensus on the diagnostic criteria, therapeutic approaches and response ...

Last Updated: 2 Dec 2015

Go To URL
Waldenstrom macroglobulinemia: prognosis and management.
 

Author(s): A Oza, S V Rajkumar

Journal:

 

Waldenstrom macroglobulinemia (WM) is a B-cell lymphoplasmacytic lymphoma characterized by monoclonal immunoglobulin M protein in the serum and infiltration of bone marrow with lymphoplasmacytic cells. Asymptomatic patients can be observed without therapy. First-line therapy should ...

Last Updated: 30 Mar 2015

Go To URL
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
 

Author(s): Meletios A Dimopoulos, Efstathios Kastritis, Roger G Owen, Robert A Kyle, Ola Landgren, Enrica Morra, Xavier Leleu, Ramón García-Sanz, Nikhil Munshi, Kenneth C Anderson, Evangelos Terpos, Irene M Ghobrial, Pierre Morel, David Maloney, Mathias Rummel, Véronique Leblond, Ranjana H Advani, Morie A Gertz, Charalampia Kyriakou, Sheeba K Thomas, Bart Barlogie, Stephanie A Gregory, Eva Kimby, Giampaolo Merlini, Steven P Treon

Journal: Blood. 2014 Aug;124(9):1404-11.

 

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As ...

Last Updated: 29 Aug 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenstrom's Macroglobulinemia

 

Last Updated: 26 Sep 2016

Go to URL
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
 

Status: Recruiting

Condition Summary: Waldenstrom Macroglobulinemia

 

Last Updated: 26 Sep 2016

Go to URL